Baseline characteristics of study participants
AD, SAD
Between 4 February 2021 and 7 September 2022, 105 healthy volunteers (HVs) were enrolled into the placebo-controlled single and multiple ascending dose escalation cohorts (SAD and MAD), and 21 HS and AD patients were enrolled into the open-label patient cohort (Fig. 